Skip to main content
. 2014 Oct 3;5(20):9577–9593. doi: 10.18632/oncotarget.2473

Figure 2. mTOR and RanBP2 proteins form a complex on the nuclear envelope.

Figure 2

(A-D) The co-localization of mTOR and RanBP2 on the nuclear envelope. Confocal images of mTOR and RanBP2 co-localization: (A) Immunostaining of mTOR in nuclei. (B) Immunostaining of RanBP2 in nuclei. (C) Nuclear staining by DAPI. (D) The merged images of mTOR and RanBP2. E-G, The immunoprecipitations of RanBP2 or mTOR from the salt extractable nuclear fraction (SENF) obtained from different human cancer cell lines have been analyzed by immunoblotting with the indicated antibodies. (E) mTOR is co-purified with RanBP2 and (F) RanBP2 is co-purified with mTOR from extracts of MDA-MB-435 cells. (G) Co-purification of RanBP2 with mTOR is specific: the shRNAs targeting luciferase (control) or mTOR were lentivirally transduced into MDA-MB-435 cells. The knock down of mTOR by expressing the specific shRNAs caused a substantial decrease in abundance of RanBP2 co-purified with mTOR antibody.